NO179615C - Monoklonale antistoffer eller fragmenter derav som reagerer med kakektin, cellelinjer som produserer dem, prövesett som omfatter dem, samt anvendelse derav in vitro - Google Patents

Monoklonale antistoffer eller fragmenter derav som reagerer med kakektin, cellelinjer som produserer dem, prövesett som omfatter dem, samt anvendelse derav in vitro

Info

Publication number
NO179615C
NO179615C NO901247A NO901247A NO179615C NO 179615 C NO179615 C NO 179615C NO 901247 A NO901247 A NO 901247A NO 901247 A NO901247 A NO 901247A NO 179615 C NO179615 C NO 179615C
Authority
NO
Norway
Prior art keywords
cell lines
cachectin
monoclonal antibodies
produce
assays
Prior art date
Application number
NO901247A
Other languages
English (en)
Norwegian (no)
Other versions
NO901247L (no
NO901247D0 (no
NO179615B (no
Inventor
George Kuo
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of NO901247L publication Critical patent/NO901247L/no
Publication of NO901247D0 publication Critical patent/NO901247D0/no
Priority to NO952509A priority Critical patent/NO180637C/no
Publication of NO179615B publication Critical patent/NO179615B/no
Publication of NO179615C publication Critical patent/NO179615C/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO901247A 1988-07-18 1990-03-16 Monoklonale antistoffer eller fragmenter derav som reagerer med kakektin, cellelinjer som produserer dem, prövesett som omfatter dem, samt anvendelse derav in vitro NO179615C (no)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NO952509A NO180637C (no) 1988-07-18 1995-06-22 Fremgangsmåte for fremstilling av monoklonale antistoffer eller fragmenter derav

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22020688A 1988-07-18 1988-07-18
PCT/US1989/003025 WO1990000902A1 (en) 1988-07-18 1989-07-12 Monoclonal antibodies reactive with cachectin

Publications (4)

Publication Number Publication Date
NO901247L NO901247L (no) 1990-03-16
NO901247D0 NO901247D0 (no) 1990-03-16
NO179615B NO179615B (no) 1996-08-05
NO179615C true NO179615C (no) 1996-11-13

Family

ID=22822529

Family Applications (1)

Application Number Title Priority Date Filing Date
NO901247A NO179615C (no) 1988-07-18 1990-03-16 Monoklonale antistoffer eller fragmenter derav som reagerer med kakektin, cellelinjer som produserer dem, prövesett som omfatter dem, samt anvendelse derav in vitro

Country Status (16)

Country Link
US (1) US5658803A (un)
EP (1) EP0351789B1 (un)
JP (1) JP2638652B2 (un)
AT (1) ATE173766T1 (un)
AU (1) AU626572B2 (un)
CA (1) CA1340018C (un)
DE (1) DE68928857T2 (un)
DK (1) DK69890A (un)
ES (1) ES2124209T3 (un)
FI (1) FI101937B1 (un)
IL (1) IL90990A (un)
NO (1) NO179615C (un)
NZ (1) NZ229922A (un)
PT (1) PT91201B (un)
WO (1) WO1990000902A1 (un)
ZA (1) ZA895372B (un)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030225254A1 (en) * 1989-08-07 2003-12-04 Rathjen Deborah Ann Tumour necrosis factor binding ligands
DK0486526T3 (da) * 1989-08-07 1996-06-24 Peptide Technology Ltd Bindingsligander for tumornekrosefaktor
US5959087A (en) * 1989-08-07 1999-09-28 Peptide Technology, Ltd. Tumour necrosis factor binding ligands
US6451983B2 (en) 1989-08-07 2002-09-17 Peptech Limited Tumor necrosis factor antibodies
GB8918232D0 (en) * 1989-08-10 1989-09-20 Opal Stephen M Pharmaceutical product for the treatment of septic shock
JPH05501351A (ja) * 1989-08-16 1993-03-18 カイロン　コーポレイション プロホルモンタンパク質に対する開裂部位阻止抗体及びその使用
DE4037604A1 (de) * 1990-04-25 1991-10-31 Bayer Ag Verwendung von anti-tnf-antikoerpern als arzneimittel bei der behandlung von ischaemien und deren folgen
WO1992002822A1 (en) * 1990-08-06 1992-02-20 Cetus Corporation Methods for the identification of cytokine convertase inhibitors
US5958413A (en) * 1990-11-01 1999-09-28 Celltech Limited Use of antibodies to TNF or fragments derived thereof and xanthine derivatives for combination therapy and compositions therefor
GB9028123D0 (en) * 1990-12-28 1991-02-13 Erba Carlo Spa Monoclonal antibodies against human tumor necrosis factor alpha
CA2100084A1 (en) * 1991-01-11 1992-07-12 James R. Rusche Method of preventing inflammatory damage
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US7192584B2 (en) 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
DE07012626T1 (de) * 1991-03-18 2010-01-21 New York University Monoklonale und chimäre Antikörper gegen humanen Tumornekrosefaktor
US5698195A (en) * 1991-03-18 1997-12-16 New York University Medical Center Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies
US5656272A (en) * 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US5919452A (en) * 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
EP0525570A3 (en) * 1991-07-31 1993-10-06 Miles Inc. Anti-idiotypic antibodies that mimic tnf
DE69321909T2 (de) * 1992-08-28 1999-04-01 Bayer Ag Verwendung von monoklonalen Anti-TNF-Antikörpern für die Behandlung von bakteriellen Meningitiden
RU2139092C1 (ru) * 1993-06-03 1999-10-10 Терапьютик Антибодиз Инк. Фрагменты антител в терапии
NZ278607A (en) * 1994-02-07 1999-05-28 Knoll Ag Use of tnf antagonists for treating disorders involving elevated serum levels of il-6 wherein the serum levels are 500pg/ml or above
AU3632595A (en) * 1994-09-15 1996-03-29 Verigen, Inc Porcine antibodies to tnf-alpha(alpha)
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
HU230048B1 (hu) 1996-02-09 2015-06-29 Abbvie Biotechnology Ltd Humán TNFalfa-kötő antitestek alkalmazása
DE19746868A1 (de) * 1997-10-23 1999-04-29 Knoll Ag Verwendung von TNF-Antagonisten als Arzneimittel zur Behandlung von septischen Erkrankungen
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
CA2817619A1 (en) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
TWI334439B (en) 2001-08-01 2010-12-11 Centocor Inc Anti-tnf antibodies, compositions, methods and uses
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
ES2347239T3 (es) 2002-12-02 2010-10-27 Amgen Fremont Inc. Anticuerpos dirigidos al factor de necrosis tumoral y usos de los mismos.
US20050045635A1 (en) * 2003-09-03 2005-03-03 Jane Dong Containers for storing articles
TWI556829B (zh) 2004-04-09 2016-11-11 艾伯維生物技術有限責任公司 用於治療ＴＮＦα相關失調症之多重可變劑量療法
NZ591701A (en) 2005-05-16 2012-11-30 Abbott Biotech Ltd Use of tnf inhibitor for treatment of erosive polyarthritis
US7662930B2 (en) * 2005-12-06 2010-02-16 Amgen Inc. Polishing steps used in multi-step protein purification processes
TWI392684B (zh) 2006-04-05 2013-04-11 Abbott Biotech Ltd 抗體之純化
WO2008063213A2 (en) 2006-04-10 2008-05-29 Abbott Biotechnology Ltd. Uses and compositions for treatment of psoriatic arthritis
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
US9399061B2 (en) 2006-04-10 2016-07-26 Abbvie Biotechnology Ltd Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis
EP2171451A4 (en) 2007-06-11 2011-12-07 Abbott Biotech Ltd METHOD FOR TREATING JUVENILIAN IDIOPATHIC ARTHRITIS
JP6078217B2 (ja) 2008-01-15 2017-02-08 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー 粉末化されたタンパク質組成物及びその作製方法
US8415291B2 (en) 2008-10-31 2013-04-09 Centocor Ortho Biotech Inc. Anti-TNF alpha fibronectin type III domain based scaffold compositions, methods and uses
WO2012149197A2 (en) 2011-04-27 2012-11-01 Abbott Laboratories Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
US9206390B2 (en) 2012-09-02 2015-12-08 Abbvie, Inc. Methods to control protein heterogeneity
JP6134392B2 (ja) 2013-01-25 2017-05-24 サイモン・エルエルシー 循環している生物学的に活性な可溶性ｔｎｆの選択的低減用の組成物およびｔｎｆ媒介性疾患を処置する方法
WO2014143205A1 (en) 2013-03-12 2014-09-18 Abbvie Inc. Human antibodies that bind human tnf-alpha and methods of preparing the same
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
EP3052640A2 (en) 2013-10-04 2016-08-10 AbbVie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
US10465003B2 (en) 2016-02-05 2019-11-05 Janssen Biotech, Inc. Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes
EP3573658A4 (en) 2017-01-30 2021-07-21 Janssen Biotech, Inc. ANTI-TNF ANTIBODIES, COMPOSITIONS, AND METHODS FOR TREATMENT OF ACTIVE PSORIATIC ARTHRITIS
WO2018147915A1 (en) 2017-02-07 2018-08-16 Janssen Biotech, Inc. Anti-tnf antibodies, compositions, and methods for the treatment of active ankylosing spondylitis
AU2020279987A1 (en) 2019-05-23 2021-11-18 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4603106A (en) * 1982-02-22 1986-07-29 The Rockefeller University Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay)
US4684623A (en) * 1985-05-02 1987-08-04 The Board Of Trustees Of The Cetus Corporation Use of tumor necrosis factor as a weight regulator
US4870163A (en) * 1985-08-29 1989-09-26 New York Blood Center, Inc. Preparation of pure human tumor necrosis factor and hybridomas producing monoclonal antibodies to human tumor necrosis factor
EP0249618A1 (en) * 1985-12-05 1987-12-23 Biogen N.V. Combinations of tumor necrosis factors and antibiotics and methods for treating tumors
US4834976A (en) * 1986-07-03 1989-05-30 Genetic Systems Corporation Monoclonal antibodies to pseudomonas aeruginosa flagella
DE3631229A1 (de) * 1986-09-13 1988-03-24 Basf Ag Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung

Also Published As

Publication number Publication date
IL90990A (en) 1994-10-21
US5658803A (en) 1997-08-19
ATE173766T1 (de) 1998-12-15
DE68928857D1 (de) 1999-01-07
PT91201B (pt) 1996-12-31
AU3970389A (en) 1990-02-19
EP0351789A2 (en) 1990-01-24
DE68928857T2 (de) 1999-08-05
WO1990000902A1 (en) 1990-02-08
DK69890D0 (da) 1990-03-16
FI101937B (fi) 1998-09-30
JP2638652B2 (ja) 1997-08-06
FI101937B1 (fi) 1998-09-30
ES2124209T3 (es) 1999-02-01
NO901247L (no) 1990-03-16
NO901247D0 (no) 1990-03-16
NZ229922A (en) 1992-04-28
JPH03501330A (ja) 1991-03-28
EP0351789B1 (en) 1998-11-25
AU626572B2 (en) 1992-08-06
IL90990A0 (en) 1990-02-09
ZA895372B (en) 1990-04-25
EP0351789A3 (en) 1990-08-01
NO179615B (no) 1996-08-05
DK69890A (da) 1990-05-15
PT91201A (pt) 1990-02-08
CA1340018C (en) 1998-09-01
FI901344A0 (fi) 1990-03-16

Similar Documents

Publication Publication Date Title
NO179615C (no) Monoklonale antistoffer eller fragmenter derav som reagerer med kakektin, cellelinjer som produserer dem, prövesett som omfatter dem, samt anvendelse derav in vitro
DE68923027D1 (de) Antigene.
NO167185C (no) Absorpsjonslegeme av fibre beregnet til bruk i engangsprodukter, samt fremgangsmaate for fremstilling av slike legemer.
NO171223C (no) Monoklonalt reseptormolekyl eller del derav som omfatter det antistoffbindende sete, for in vitro bruk, samt in vitro anvendelse derav
DE3886760T2 (de) Monoklonale antikörper gegen menschliche interleukin-4 und die sie erzeugenden hybridomen.
IT8024313A0 (it) Montatura e procedimento per montare pietre preziose e simili nella detta montatura.
DK115189A (da) Sulfateret k5-antigen og sulfaterede k5-antigenfragmenter og fremgangsmaade til fremstilling deraf samt middel indeholdende det sulfaterede k5-antigen eller fragmenter deraf
EP0341684A3 (en) Human monoclonal antibody, hybridoma producing the same and pharmaceutical
IT8820023A0 (it) Struttura di braccialetti, anelli, cinturini e simili, dotata di mezzi indicatori.
DE3585049D1 (de) Monoklonale antikoerper.
FR2689904B1 (fr) Test de bronzage épidermique in vitro.
ES2046187T3 (es) Anticuerpos para uso en la determinacion de la glucoalbumina humana.
DE69034209D1 (de) 2'-deoxy-4'-thioribonucleoside als antivirale und antikrebsmittel
NO894378L (no) Blandeapparat, samt tilhoerende fremgangsmaate.
TR25221A (tr) ISLAH EDILMIS YUMUSAKLIGA SAHIP YAGLANMIS DERILER VE BUNLARIN üRETILMESINE MAHSUS USUL.
ATE51894T1 (de) Spezifische mycoplasma-membran-antigene und antik¯rper sowie deren klinische verwendungen.
DE68909937D1 (de) Sicherheitsanordnung im flugzeugladeraum.
NO864742D0 (no) Dna-sekvens som koder for human vevsplasminogenaktivator, rekombinant dna-sekvens, vertcelle transformert med denne samt fremgangsmaate for fremstilling av plasminogenaktivatoren.
IT8848161A0 (it) Dispositivo per la trasformazione di motociclette e simili, in mezzi aerei
IT8821811A0 (it) Metodo per il rivestimento di gallerie mediante l'impiego di lastre in policarbonato, e mezzi adatti allo scopo.
ES241072Y (es) Mejoras introducidas en las cabinas de granallado.
FI880188A0 (fi) Wobbler med flere funktioner.
NO911715L (no) Forbedrede polyoler, fremgangsmaate for deres fremstilling, samt anvendelse.
ES243582Y (es) Mejoras introducidas en la aireacion de cabinas y similares.
ES1007529Y (es) Dispositivo de acoplamiento para la constitucion de estufas en botellas de gas.

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees

Free format text: LAPSED IN JANUARY 2003